Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
May 28, 2024 06:59 ET
|
Pasithea
Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's
TAFINLAR + MEKINIST Drug Insight and Market Outlook to 2032 in Glioblastoma Multiforme Treatment Scenario
January 02, 2024 05:33 ET
|
Research and Markets
Dublin, Jan. 02, 2024 (GLOBE NEWSWIRE) -- The "TAFINLAR + MEKINIST Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report delves deep into...
Global Thyroid Cancer Drugs Market to Reach $1.29 Billion by 2027: Targeted Therapies Transforming Thyroid Cancer Treatment
July 31, 2023 05:33 ET
|
Research and Markets
Dublin, July 31, 2023 (GLOBE NEWSWIRE) -- The "Thyroid Cancer Drugs Global Market Report 2023" has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive guide to...
Global MEK Inhibitors Market, Drug Sales & Clinical Trials to 2026: USD 3 Billion Market Opportunity
November 19, 2021 05:03 ET
|
Research and Markets
Dublin, Nov. 19, 2021 (GLOBE NEWSWIRE) -- The "Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026" report has been added to ResearchAndMarkets.com's offering. The advances...